Soliris Market Report 2026

Soliris Market Overview

• The Soliris market growth in the historic period has been driven by unmet needs in rare diseases, clinical success in pnh and ahus • Market expansion is supported by expansion into additional complement mediated diseases, rising rare disease awareness • Growth Driver: Growing Prevalence Of Rare Blood Disorders To Drive Soliris Market Expansion • Market Trend: NMPA Approval Of Eculizumab For Rare Blood Disorder Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Soliris Market?

Soliris (eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals. It inhibits the complement protein C5, reducing inflammation and damage caused by an overactive immune system. Soliris is primarily used to treat rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). The main types of Soliris are plasma exchange and plasma infusion. Plasma exchange is a medical procedure that removes and replaces a patient's plasma to treat various conditions, such as autoimmune disorders or blood disorders. For applications in paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (AHUS) and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Soliris Market Growth Forecast?

The soliris market size is expected to see strong growth in the next few years. It will grow to $2941.58 million in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to expansion into additional complement mediated diseases, rising rare disease awareness, growth in genetic diagnostics, increased healthcare funding for orphan drugs, long term therapy adherence programs. Major trends in the forecast period include rising adoption of complement inhibitor therapies, growing focus on ultra rare diseases, expansion of long term biologic treatment use, increased genetic testing for rare disorders, high value orphan drug market growth.

Global Soliris Market Segmentation

1) By Type: Plasma Exchange, Plasma Infusion 2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS) 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Soliris Market?

The increasing prevalence of rare blood disorders is expected to propel the growth of the soliris market going forward. Rare blood disorders refer to uncommon conditions affecting the blood's production, components, or clotting, such as hemophilia, sickle cell anemia, and thalassemia. The rise in the prevalence of rare blood disorders is attributed to improved diagnostic techniques, greater awareness, and genetic and environmental factors. Soliris inhibits the complement protein C5 that helps rare blood disorder patients by preventing excessive complement activation, which reduces the risk of severe complications such as hemolysis and organ damage, thereby improving overall disease management and patient outcomes. For instance, in May 2024, according to the National Health Service (NHS) England, a UK-based government-funded healthcare system, in England, approximately 17,000 people are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Therefore, the increasing prevalence of rare blood disorders is driving the growth of the soliris industry. The growing investment in rare disease research is expected to propel the growth of the Soliris market going forward. The rise in rare disease research investment is driven by the increasing recognition of unmet medical needs, advancements in genomics, and the potential for breakthrough therapies that can improve patient outcomes. Investment in rare disease research helps Soliris by expanding the understanding of underserved conditions, leading to increased demand for effective treatments. For instance, in July 2023, the Department of Health and Science Care, a UK-based government department, provided significant funding including USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which connects genetic data to clinical traits across 50 rare diseases to enhance diagnostic and treatment development. Therefore, the growing investment in rare disease research is driving the growth of the Soliris industry.

Key Players In The Global Soliris Market

Major companies operating in the soliris market are Pfizer

Global Soliris Market Trends and Insights

The key trend in the soliris market is focusing on developing biologic medicines for neuromyelitis optica spectrum disorder (NMOSD) to enhance treatment options for rare blood disorders. This marks a significant advancement in the management of NMOSD, a rare and debilitating autoimmune disease affecting the central nervous system, by providing an effective therapy to reduce relapses and prevent further neurological damage. For instance, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, received approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This marks the first and only complement inhibitor approved for NMOSD treatment in China.

Regional Insights

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Soliris Market?

The soliris market consists of sales of soliris (eculizumab) 300 mg/30 mL vial, soliris (eculizumab) injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Soliris Market Report 2026?

The soliris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the soliris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.